Disappointing trials from XBiotech, Merrimack Pharmaceuticals, and NewLink Genetics have earned the market's ire. But are their declines overdone?
News & Analysis: Merrimack Pharmaceuticals
These stocks led the market lower. Find out why.
The biotech's managerial shake-up is wreaking havoc on its share price.
This biotech hopes to recapture its luster following a major restructuring.
Here's why it could make sense for Twitter, GoPro, and Merrimack Pharmaceuticals to get acquired.
Investors fled the stock after the company announced a major restructuring of its business.
It was an eventful year for the commercial-stage biotech. Let's take a closer look at the key events that caused the company's stock to get cut in half.
Merrimack hits the reset button.
A mid-stage trial for a breast cancer drug candidate was stopped after interim results suggested it wasn't likely to compete with drugs already on the market.
The results of the general election have investors optimistic about the future of regulations affecting the industry.